Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aimmune Therapeutics, Inc.
This is a Phase 3, multi-center, North American, open-label, long-term, safety extension study for eligible subjects who received AR101 therapy in the ARC007 trial (NCT03126227) and completed the study.
Age
4–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Received AR101 in study ARC007
Completed the ARC007 study
Use of effective birth control by sexually active female subjects of childbearing potential
You may not be if
Developed a clinically significant change in health status during the ARC007 study which in the opinion of the investigator would make the subject unsuitable for participation in this study.
Receiving a prohibited medication or anticipated use of a prohibited medication \[e.g., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers or calcium channel blockers\], any monoclonal antibody, any investigational peanut immunotherapy, or any other immunomodulatory therapy.
Currently in the build-up phase of immunotherapy for any nonfood allergen.
Currently participating in any other interventional clinical study outside of the ARC007 study that was just completed.
Clareo Health | AR101 Real-World Open-Label Extension Study
